Admedus Charts An Eclectic Path To A Global Future
Executive Summary
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
You may also be interested in...
Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Philips Strikes Record High Number Of Long Term Health Care Partnership Deals
Royal Philips closed out the first year of COVID-19 with 7% revenue growth in the fourth quarter. CEO Frans van Houten says low single digit growth is the target for fiscal 2021.
UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports